Estramustine - CAS 2998-57-4
Catalog number:
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Estramustine, a derivative of estradiol, is an alkylating antineoplastic agent that is used in the treatment of prostate cancer throughout the world.
Publictions citing BOC Sciences Products
  • >> More
Crystalline solid
[(8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] N,N-bis(2-chloroethyl)carbamate;
Soluble in DMSO
Store at -20 °C
Used treatment of breast cancer. Also used in the treatment of prostate cancer.
Quality Standard:
Enterprise standard
Shelf Life:
As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly.
Canonical SMILES:
1.Androgen-deprivation therapy plus chemotherapy in metastatic hormone-sensitive prostate cancer. A systematic review and meta-analysis of randomized clinical trials.
Ramos-Esquivel A1, Fernández C2, Zeledón Z3. Urol Oncol. 2016 Apr 1. pii: S1078-1439(16)00085-5. doi: 10.1016/j.urolonc.2016.03.003. [Epub ahead of print]
OBJECTIVE: To assess the efficacy and toxicity of androgen-deprivation therapy (ADT) plus chemotherapy in patients with hormone-sensitive metastatic prostate cancer.
2.Effective and Safe Administration of Low-Dose Estramustine Phosphate for Castration-Resistant Prostate Cancer.
Inoue T1, Ogura K2, Kawakita M3, Tsukino H4, Akamatsu S1, Yamasaki T1, Matsui Y1, Segawa T5, Sugino Y3, Kamoto T4, Kamba T1, Tanaka S6, Ogawa O7. Clin Genitourin Cancer. 2016 Feb;14(1):e9-e17. doi: 10.1016/j.clgc.2015.08.008. Epub 2015 Sep 2.
BACKGROUND: We evaluated the efficacy and safety of low-dose estramustine phosphate (EMP) in Japanese patients with castration-resistant prostate cancer (CRPC).
3.Concurrent chemoradiation for high-risk prostate cancer.
Cooper BT1, Sanfilippo NJ1. World J Clin Oncol. 2015 Aug 10;6(4):35-42. doi: 10.5306/wjco.v6.i4.35.
There are estimated to be 220800 cases of prostate cancer diagnosed in 2015, making up 26% of all cancer diagnoses. Fortunately, adenocarcinoma of the prostate is often a highly treatable malignancy. Even though the majority of prostate cancer patients present with localized disease, prostate cancer still accounts for over 27000 deaths a year. There is a subset of patients that are likely to recur after locoregional treatment that is thought of as a "high-risk" population. This more aggressive subset includes patients with clinical stage greater than T2b, Gleason score greater than 7, and prostate specific antigen greater than 20 ng/dL. The rate of biochemical relapse in this high risk group is 32%-70% within five years of definitive focal therapy. Given these discouraging outcomes, attempts have been made to improve cure rates by radiation dose escalation, addition of androgen depravation therapy, and addition of chemotherapy either sequentially or concurrently with radiation.
4.A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902.
Rosenthal SA1, Hunt D2, Sartor AO3, Pienta KJ4, Gomella L5, Grignon D6, Rajan R7, Kerlin KJ8, Jones CU9, Dobelbower M10, Shipley WU11, Zeitzer K12, Hamstra DA13, Donavanik V14, Rotman M15, Hartford AC16, Michalski J17, Seider M18, Kim H19, Kuban DA20, Mou Int J Radiat Oncol Biol Phys. 2015 Oct 1;93(2):294-302. doi: 10.1016/j.ijrobp.2015.05.024. Epub 2015 Jul 21.
PURPOSE: Long-term (LT) androgen suppression (AS) with radiation therapy (RT) is a standard treatment of high-risk, localized prostate cancer (PCa). Radiation Therapy Oncology Group 9902 was a randomized trial testing the hypothesis that adjuvant combination chemotherapy (CT) with paclitaxel, estramustine, and oral etoposide plus LT AS plus RT would improve overall survival (OS).
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products

CAS 472-61-7 Astaxanthin

(CAS: 472-61-7)

Carotenoid pigment found mostly in animal organisms, but also occuring in plants; thought to be the precursor of astacin. Astaxanthin is a carotenoid pigment fo...

KHK-IN-1 hydrochloride
(CAS: 1303470-48-5)

The hydrochloride salt form of KHK-IN-1 which is a ketohexokinase inhibitor that could have probable effect against diabetes and obesity by acting on Asp-27B in...

CGP 43182
(CAS: 150379-37-6)

CGP 43182, a dioxaspiro compound, has been found to a IIA sPLA2 inhibitor that could have potential anti-inflammatory effect and also in influencing the synergi...

CAS 210110-90-0 Miglustat HCl

Miglustat HCl
(CAS: 210110-90-0)

Miglustat hydrochloride is an inhibitor of glucosylceramide synthase, primarily to treat Type I Gaucher disease (GD1).

CAS 382-67-2 Desoximetasone

(CAS: 382-67-2)

Desoximetasone is a synthetic corticosteroid, a class of primarily synthetic steroids used as anti-inflammatory and anti-pruritic agents, which is used for the ...

CAS 856095-68-6 OBA-09

(CAS: 856095-68-6)

OBA-09 is a novel multimodal neuroprotective agent. It is an ester of pyruvate and salicylic acid that acts as a multi-functional agent to protect against ische...

(CAS: 17518-97-7)

CP-60949-4, a quinazolin derivative, could be probably useful in sorts of biological studies.

CAS 70831-56-0 L-Chicoric acid

L-Chicoric acid
(CAS: 70831-56-0)

Cichoric acid, that can be isolated from the herbs of Echinacea purpurea, is an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase in vitro.

(CAS: 179054-51-4)

FR-182980, a pyridine derivative, has been found to be a sterol O-acyltransferase inhibitor and was once studied in hypercholesterolaemia.

CAS 306-20-7 Fenaclonum

(CAS: 306-20-7)

Fenaclon is a pharmaceutical intermediate.

CAS 1188-38-1 N-Carbamyl-L-Glutamic acid

N-Carbamyl-L-Glutamic acid
(CAS: 1188-38-1)

N-Carbamyl-L-Glutamic acid is an orphan drug which is applicated for the treatment of hyperammonaemia in patients that has N-acetylglutamate synthase deficiency...

CAS 5581-42-0 Glyparamide

(CAS: 5581-42-0)

Glyparamide is a chlorophenyl-containing sulfonylurea with hypoglycemic activity and rarely causes hepatic injury.

(CAS: 194213-64-4)

BMS-212122 is a benzimidazole-based analogue of the potent MTP inhibitor BMS-201038.

CAS 355129-15-6 Eprotirome

(CAS: 355129-15-6)

Eprotirome is a synthetic thyroid hormone mimetic as a thyroid hormone receptor beta agonists, lowers total and low-density lipoprotein cholesterol up to 40% wi...

CAS 102040-03-9 Tubeimoside I

Tubeimoside I
(CAS: 102040-03-9)

Tubeimoside I is a triterpene saponin originally isolated from Bolbostemma that exhibits anti-inflammatory, antiviral, anticancer chemotherapeutic, and chemopre...

CAS 129558-76-5 Tolfenpyrad

(CAS: 129558-76-5)

Tolfenpyrad is used as foliar insecticide for the control of green peach aphids in broccoli.

CEP dipeptide 1
(CAS: 816432-15-2)

CEP dipeptide 1 is a CEP dipeptide which has potent angiogenic activity. It is used as mediators of age-related macular degeneration (AMD).

CAS 269730-03-2 RPI-1

(CAS: 269730-03-2)

RPI-1 is a cell-permeable, ATP-dependent RET kinase inhibitor. Oral treatment with RPI-1 caused growth arrest or regression in 81% treated tumors. It can also b...

CAS 56180-94-0 Acarbose

(CAS: 56180-94-0)

Acarbose is an inhibitor of intestinal alpha-glucosidase, used to treat type 2 diabetes mellitus.

CAS 115-02-6 Azaserine

(CAS: 115-02-6)

Azaserine is a naturally occurring serine derivative diazo compound with antineoplastic properties, Azaserine functions as a purine antagonist and glutamine ana...

Chemical Structure

CAS 2998-57-4 Estramustine

Quick Inquiry

Verification code

Featured Items